Australian Clinical Labs Ltd
ASX:ACL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Australian Clinical Labs Ltd
ASX:ACL
|
AU |
|
A
|
Athabasca Oil Corp
OTC:ATHOF
|
CA |
|
Ferrovial SE
AEX:FER
|
NL |
Wall St Price Targets
ACL Price Targets Summary
Australian Clinical Labs Ltd
According to Wall Street analysts, the average 1-year price target for ACL is 2.78 AUD with a low forecast of 2.283 AUD and a high forecast of 3.36 AUD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ACL's stock price target?
Price Target
2.78
AUD
According to Wall Street analysts, the average 1-year price target for ACL is 2.78 AUD with a low forecast of 2.283 AUD and a high forecast of 3.36 AUD.
What is the Revenue forecast for Australian Clinical Labs Ltd?
Projected CAGR
5%
Over the last 8 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 7 years is 5%.
What is the Gross Profit forecast for Australian Clinical Labs Ltd?
Projected CAGR
-5%
Over the last 8 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 7 years is -5%.
What is the Operating Income forecast for Australian Clinical Labs Ltd?
Projected CAGR
7%
The compound annual growth rate for Operating Income over the next 7 years is 7%.
What is the Pre-Tax Income forecast for Australian Clinical Labs Ltd?
Projected CAGR
20%
The compound annual growth rate for Pre-Tax Income over the next 2 years is 20%.
What is the Net Income forecast for Australian Clinical Labs Ltd?
Projected CAGR
15%
The compound annual growth rate for Net Income over the next 7 years is 15%.
